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Abstract
In many aggressive cancers, such as glioblastoma multiforme (GBM), progression is enabled by 
local immunosuppression driven by the accumulation of regulatory T cells (Treg) and myeloid-
derived suppressor cells (MDSC). However, the mechanistic details of how Treg and MDSC are 
recruited in various tumors is not yet well understood. Here we report that macrophages and 
microglia within the glioma microenvironment produce CCL2, a chemokine that is critical for 
recruiting both CCR4+ Treg and CCR2+Ly-6C+ monocytic MDSC in this disease setting. In 
murine gliomas, we established novel roles for tumor-derived CCL20 and osteoprotegerin in 
inducing CCL2 production from macrophages and microglia. Tumors grown in CCL2 deficient 
mice failed to maximally accrue Treg and monocytic MDSC. In mixed-bone marrow chimera 
assays, we found that CCR4-deficient Treg and CCR2-deficient monocytic MDSC were defective 
in glioma accumulation. Further, administration of a small molecule antagonist of CCR4 improved 
median survival in the model. In clinical specimens of GBM, elevated levels of CCL2 expression 
correlated with reduced overall survival of patients. Lastly, we found that CD163-positive 
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infiltrating macrophages were a major source of CCL2 in GBM patients. Collectively, our findings 
show how glioma cells influence the tumor microenvironment to recruit potent effectors of 
immunosuppression that drive progression.
INTRODUCTION
Immune evasion is a major hallmark of tumorigenesis and a potent barrier to effective cancer 
therapies (1). In a wide spectrum of cancer types, immune evasion manifests as the 
recruitment of immunosuppressive regulatory T cells (Tregs) and myeloid-derived 
suppressor cells (MDSCs) to the tumor microenvironment. Tregs are a FOXP3-expressing 
subset of CD4+ T cells which play an important role in maintaining immunological tolerance 
to self under normal physiological conditions (2). However, Treg infiltration occurs in a 
variety of cancer types and is correlated with worse prognosis in breast, ovarian, gastric, and 
esophageal cancers (3–5). MDSCs are thought to originate from monocytes that gain 
immunosuppressive capacity under certain pathological conditions (6,7). Human MDSCs 
are characterized by the pan-myeloid marker CD33, with monocytic CD14+ and 
granulocytic CD15+ subsets. Murine MDSCs are defined as CD11b+Gr-1+ cells, with 
monocytic Ly-6C+ and granulocytic Ly-6G+ cellular subsets.
Glioblastoma multiforme (GBM) (WHO Astrocytoma Grade IV) is the most common 
malignant adult brain tumor with a dismal prognosis for patients. Median survival of GBM 
is just 14.6 months even with the treatment standard of surgery, radiation, and chemotherapy 
(8). The GBM microenvironment is characterized by high levels of immunosuppressive 
cytokines as well as the accumulation of Tregs and MDSCs (9–13). In gliomas, Treg 
infiltration is higher in GBM compared to lower grade astrocytomas, though conflicting 
reports exist on the prognostic value of Treg infiltration (9,10,14). Increased peripheral 
MDSCs have been observed in GBM patients (15). In addition, monocytes from healthy 
donors acquire MDSC characteristics when treated with conditioned media from GBM cell 
lines (12). Despite the importance of these cells for the progression of GBM, the 
mechanistic sequence of events underlying the recruitment of these cells has yet to be 
elucidated.
CCL2 is a potential candidate chemokine for Treg trafficking to glioma. Supernatant from 
cultured U251 GBM cells contains soluble CCL2 and can induce Treg migration in vitro 
(16). Patients with GBM possess an increased percentage of circulating Tregs that express 
CCR4, a chemokine receptor that binds to CCL2, albeit with lower affinity than for CCL17 
and CCL22 (16,17). CCL2 has also been tied to the migration of MDSCs. CCR2, a high 
affinity chemokine receptor for CCL2, is found on several different myeloid cell 
populations, including MDSCs (18). Virally induced gliomas in Ccl2−/− mice possess 
markedly reduced MDSC infiltration (15). Although these studies have implicated a 
potential role for the CCL2-CCR4/CCR2 axis, the sequence of events from the induction of 
CCL2 production to the in vivo chemokine-chemokine receptor requirements for Tregs and 
MDSC recruitment remains incompletely understood. We hypothesized that CCL2 recruits 
both Tregs and MDSCs in GBM, thus unifying the two immunosuppressive cell subsets 
under one axis. We sought to determine the clinical relevance of CCL2 in large scale patient 
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data, identify sources of CCL2, and elucidate the underlying mechanisms driving Treg and 
MDSC accumulation. In this report, we determined that CCL2 expression is a prognostic 
factor for patients with GBM and can be produced by both macrophages as well as glial 
cells in GBM patient samples. In addition, we observed that CD163+ infiltrating 
macrophages contribute to CCL2 production in GBM patients. In the GL261 
immunocompetent murine model of GBM, we found that tumor-associated macrophages 
and microglia are major sources CCL2 which subsequently recruits CCR4-expressing Tregs 
and CCR2-expressing Ly-6C+ monocytic MDSCs. We established novel roles for tumor-
derived CCL20 and osteoprotegerin in inducing CCL2 production from macrophages and 
microglia. Through mixed-bone marrow chimera studies, we observed a role for CCR4 in 
Treg recruitment and a requirement for CCR2 in the accumulation of monocytic MDSCs in 
glioma. Finally, using a small molecule antagonist, we demonstrated that the CCL2-CCR4/2 
axis is a relevant therapeutic target in GBM. Collectively, these studies delineate how 
microenvironment-derived CCL2 results in the accumulation of Tregs and MDSCs in 
glioma.
MATERIALS AND METHODS
Cell culture
GL261 cells (NCI Frederick National Tumor Repository Lab, obtained in 2007) and mixed-
cortical cell cultures were cultured in Dulbecco’s Modified Eagle’s Medium (Corning) 
supplemented with 10% Fetal Bovine Serum (FBS), penicillin/streptomycin solution, and 
Normocin (InvivoGen). Cell line authentication was not conducted at this time. Microglia 
were cultured in X-VIVO 15 (Lonza). Bone marrow cells, bone marrow-derived 
macrophages, and Tregs were cultured in RPMI Medium 1640 (Corning) supplemented with 
penicillin/streptomycin, L-glutamine, β-mercaptoethanol, and FBS.
Mice
All mice were bred and housed under SPF conditions in the Carlson Barrier Facility at the 
University of Chicago. Wild-type C57BL/6J mice (Stock 000664), Ccl2−/− mice (B6.129S4-
Ccl2tm1Rol/J, Stock 004434), Ccr2RFP/RFP mice (B6.129(Cg)-Ccr2tm2.1Ifc/J, Stock 
017586), and CD45.1+ mice (B6.SJL-Ptprca Pepcb/BoyJ, Stock 002014), were purchased 
from The Jackson Laboratory. Ccr4−/− mice were kindly provided by Dr. John Belperio 
(University of California Los Angeles).
Patient data
A detailed description can be found in the Supplementary Materials and Methods section.
Immunohistochemistry
A detailed description can be found in the Supplementary Materials and Methods section.
Orthotopic GL261 model of GBM
4 × 105 GL261 cells were intracranially (i.c.) implanted as previously described (19). Mice 
were treated with the small molecule CCR4 antagonist C 021 dihydrochloride (Tocris) at 15 
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mg/kg-50 mg/kg doses administered subcutaneously every other day for a total of 5 doses 
beginning 1 day post-i.c. GL261 implantation.
Immunofluorescence microscopy
A detailed description can be found in the Supplementary Materials and Methods section.
Bone marrow-derived macrophages and cytokine treatment
A detailed description can be found in the Supplementary Materials and Methods section.
Mixed-cortical cell cultures and isolation of microglia
Performed according to a previously published protocol (20).
ELISA
The Ready-Set-Go! Mouse CCL2 ELISA Kit (EBioscience) was used according to 
manufacturer’s protocol.
Antibody array
Supernatant from GL261 cultures or MCCC were incubated with the Mouse Cytokine Array 
C6 (AAM-CYT-6, RayBiotech) and developed according to manufacturer’s protocol. Film 
was scanned and analyzed for densitometry using ImageJ.
Flow cytometry
Tissue preparation and flow cytometric analysis was completed as previously published (19).
Mixed-bone marrow chimera generation and competition assay
Recipient mice at least 6 weeks of age were irradiated with 1100 cGy using a Gammacell 40 
Exactor irradiator (Theratronics). 24 hours post-irradiation, mice were injected with a 1:1 
ratio of WT CD45.1+ bone marrow cells or bone marrow cells from CCR4-deficient or 
CCR2-deficient mice. After 6 weeks following bone marrow reconstitution, mice were 
injected intracranially with GL261 cells and used for experiments.
Statistics
Groups were compared with Student’s two-tailed t test or one-way ANOVA with Tukey’s 
test for multiple comparisons as indicated in figure legends. A P value of less than 0.05 was 
considered statistically significant. Survival curves were compared with the Log-rank test, 
corrected using the Bonferroni method if multiple survival curves were compared. All 
statistical tests were done using either Prism 6.0 (Graphpad) or Stata (Statacorp).
Study approval
All animal experiments were approved by the Institutional Animal Care and Use Committee 
at the University of Chicago.
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RESULTS
CCL2 is a clinically relevant prognostic factor in GBM patients
To determine the clinical relevance of CCL2, we obtained gene expression data and clinical 
parameters from GBM patient data available through The Cancer Genome Atlas (TCGA). 
Patients were stratified into CCL2-high and CCL2-low groups based on CCL2 gene 
expression. Median survival was significantly increased in CCL2-low subset patients in data 
encompassing all glioma grades (Figure 1A) as well as in data limited to GBM cases alone 
(Figure 1B) when compared to the CCL2-high subset (Affymetrix U133A: CCL2-low 479 
days, CCL2-high 375 days, P < 0.001) (Illumina HiSeq: CCL2-low 485 days, CCL2-high 
317 days, P = 0.003). CCL2 expression was confirmed as a prognostic factor in GBM 
patients through both univariate and multivariate Cox regression analysis (HR=1.11). In 
contrast to CCL2, gene expression levels of CCL1, CCL3, CCL4, and CCL28 did not 
segregate GBM patient survival (Supplementary Figure S1A–D). To survey CCL2 protein 
levels in GBM, we performed immunohistochemical staining of CCL2 on a GBM patient 
tissue microarray with 35 GBM cases with 2 cores from each case (Supplementary Figure 
S1H–I). In non-tumor brain biopsies, CCL2 expression was scored as 0 (Figure 1C, left). In 
contrast, among the 35 GBM cases available on the tissue microarray, 16 cases were scored 
as 0 (no CCL2 staining), 6 cases were scored as 1 (low), 9 cases were scored as 2 (medium), 
and 4 cases were scored as 3 (highest staining). CCL2 expression was also correlated to the 
expression of the human MDSC markers CD33 (r = 0.56, P < 0.001) and CD14 (r = 0.70, P 
< 0.01), as well as the expression of CD4 (r = 0.56, P < 0.001) (Figure 1D–1G). Importantly, 
CCL2 expression was not correlated to the expression of the pan-T cell marker CD3, 
implying some specificity to the correlation with CD4 and MDSC markers (Figure 1G). 
Overall, the results suggest that CCL2 mRNA expression serves as an important prognostic 
factor for survival in GBM and the clinical relevance of CCL2 extends to its presence on a 
protein level in GBM patient samples.
CD163-positive macrophages contribute to CCL2 production in GBM patients
Previous reports have found that CCL2 can be produced by astrocytes in the context of 
neuroinflammation and by tumor cells in the context of glioma (16,21,22). However, 
because CCL2 can also be produced by tumor-associated macrophages, we sought to 
determine the respective contributions of glial cells compared to macrophages and microglia 
for CCL2 production in GBM patients on a protein level (23,24). To this end, we performed 
double-immunofluorescence labeling of CCL2 and the macrophage/microglia marker 
CD163 in formalin-fixed, paraffin-embedded sections from 20 GBM patients. We opted for 
whole sections to ensure extensive anatomical coverage of GBM tumor areas. We observed 
heavy infiltration of CD163+ cells that were morphologically infiltrating macrophages in 
13/20 GBM cases. CCL2 staining was found in both cellular tumor areas as well as in 
perinecrotic zones. We observed strong CCL2 immunoreactivity in both CD163+ cells as 
well as in CD163− cells in the cases with heavy CD163+ cell infiltration (Figure 2A). We 
observed CCL2 immunoreactivity in CD163+ (Figure 2A, GBM case 256) as well as in both 
CD163+ and CD163− cells (Figure 2A, GBM case 376A1 and 257). The CD163− cells that 
produce CCL2 are most likely tumor cells, per previous reports. Therefore, both tumor cells 
as well as glioma-associated macrophages are capable of producing CCL2 in GBM patients.
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CCL2 is a major microenvironment-derived Treg and MDSC-recruiting candidate 
chemokine in the GL261 model of GBM
We next investigated the GL261 murine model of GBM to determine the role of CCL2 
directly. In this model, Tregs and MDSCs accumulate in the brain after syngeneic GL261 
astrocytoma cells are implanted into C57BL/6 mice (19). We determined CCL2 transcript 
expression localization in GL261-bearing brains at 1 week post-injection, during the 
recruitment phase for Tregs and MDSCs. Strikingly, high CCL2 transcript levels were found 
within leukocytes isolated by density gradient centrifugation, ~20 fold over PBS control in 
the whole leukocyte preparation compared to 5-fold over PBS control in non-leukocytes 
(Supplementary Figure S2A). CCL2 was also detected on the protein level via ELISA (260 
± 33 ng/mL in the GL261-injected hemisphere compared to 93 ± 7 ng/mL in the non-
GL261-injected hemisphere, P = 0.0075, mean ± SEM) (Supplementary Figure S2B) and 
immunofluorescence microscopy (Supplementary Figure S2C) from the brains of mice at 1 
week post-intracranial (i.c.) injection of GL261 cells. Furthermore, CCL2 was expressed at 
the highest level at 1 week post-GL261 injection compared to other candidate Treg and 
MDSC-recruiting chemokines (Supplementary Figure S2D). Collectively, these data indicate 
that CCL2 is present both at the mRNA and protein level in murine brain tumors and that a 
major source of CCL2 lies within leukocytes in the glioma microenvironment.
CD11b+ macrophages and microglia are the primary source of CCL2 in the GL261 model
To identify the cellular source of CCL2 in the GL261 model, immunofluorescence staining 
of tissue sections was performed at 1-week post-i.c. implantation of GL261 cells (Figure 
2B). CCL2 immunoreactivity was detected in the vicinity of CD11b+ and Iba-1+ cells only 
in the context of GL261 brain tumors, but not in the brains of naïve mice. We performed 
intracellular cytokine staining and found that CCL2 expression was predominantly confined 
to CD45intCD11b+ microglia (~60% CCL2-positive) and CD45highCD11b+Ly-6G− 
macrophages (~70% CCL2-positive) (Figure 2C). In contrast, a low percentage of CD4+ T 
cells and CD11b+Ly-6G+ granulocytic MDSCs expressed CCL2 (~10% for both CD4+ T 
cells and granulocytic MDSCs) (Figure 2C). Given that CCL2 can be produced by myeloid 
cells stimulated with various polarizing conditions, we next determined the M1 or M2 status 
of glioma-associated microglia and macrophages in our model to identify candidate 
cytokines responsible for inducing CCL2 production in these cells (25). Microglia from 
GL261 tumors demonstrated an increased expression of Arginase-1 (Arg1) relative to 
microglia from PBS-injected control brains (Figure 2D). When compared to peripheral 
macrophages, glioma associated macrophages express a ~600 fold greater Arg1 mRNA level 
while glioma-associated microglia express a 60-fold greater Arg1 mRNA level (Figure 2E). 
Thus, the major sources of CCL2 in GL261 gliomas are Arg1-expressing glioma-associated 
macrophages and microglia.
A soluble GL261-derived factor induces CCL2 production from macrophages and microglia
Since tumor-associated macrophages and microglia are major sources of CCL2, we 
hypothesized that GL261-derived factors induce CCL2 production from these cells. To test 
this hypothesis, we treated bone marrow-derived macrophages (BMDMs) and microglia 
isolated from mixed-cortical cell cultures (MCCC) with conditioned media from GL261 
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cells. GL261-conditioned media induced CCL2 production from both macrophages (1881 
± 40 ng/mL in conditioned media treated macrophages vs. 520 ± 23 ng/mL in control, P < 
0.0001, mean ± SEM) and microglia (101.3 ± 5.1 ng/mL in conditioned media treated 
microglia vs. 56.9 ± 0.1 ng/mL in control, P < 0.01) as determined by ELISA (Figure 3A–
3B). We also assessed the impact of cytokine stimuli on CCL2 production. LPS + IFNγ 
induced CCL2 production from BMDMs and microglia whereas CCL2 production from 
BMDMs was decreased after treatment with TGFβ or TNFα (42.8 ±3.9 ng/mL in TGFβ-
treated BMDMs and 120.3 ± 15.7 ng/mL in TNFα-treated BMDMs, P < 0.001, mean ± 
SEM) (Figure 3A–3B). Collectively, these data suggest that soluble factors derived from 
GL261 cells induce CCL2 secretion from macrophages and microglia. Consequently, we 
performed antibody arrays using GL261 supernatant and MCCC supernatant to selectively 
identify tumor microenvironment-specific soluble factors (Figure 3C–3D and 
Supplementary Table S1). Using this approach, we identified osteoprotegerin (OPG), 
osteopontin (OPN), soluble TNF receptor type II (sTNFRII), CCL5, CCL20, and CXCL2. 
Among these candidate cytokines, only OPG and CCL20 were sufficient to induce CCL2 
production in vitro (Figure 3E–3G). These data collectively suggest that factors secreted by 
glioma cells induce CCL2 expression in microglia and macrophages in a non-cell 
autonomous fashion.
GL261 tumors are infiltrated by CCR4+ Tregs and CCR2+ MDSCs
We next determined which cells in the glioma microenvironment express chemokine 
receptors recognizing CCL2. Flow cytometric analysis of GL261-bearing brains at 1 week 
post-tumor implantation found that CCR4 was expressed by 60% CD3+CD4+Foxp3+ Tregs, 
while CCR2 was localized to CD3−CD45+CD11c−CD11b+ MDSC populations (Figure 4A 
and Supplementary Figure S3). In contrast, CD8+ T cells did not express high percentages of 
either CCR4 or CCR2 (Figure 4A–4B). The highest percentages of CCR4+ Tregs were 
observed in the brain compared to cervical lymph nodes (cLNs) or the spleen, suggesting 
that the accumulation of CCR4+ Tregs is specific to brain tumors (Figure 4C–4D). Both 
MDSC subtypes accumulated in the brain at 1 week post-i.c. GL261 implantation and are 
virtually absent in PBS-injected controls (Figure 4E–4F). Both tumor-infiltrating 
granulocytic Ly-6G+ MDSCs and monocytic Ly-6C+ MDSCs expressed CCR2 (Figure 4G–
4H). In contrast, CD45intCD11b+ microglia expressed minimal CCR2 or CCR4. In total, 
these results suggest that both Treg and MDSC populations possess chemokine receptors 
required for responding to CCL2 in the glioma microenvironment.
Tregs and Ly-6C+ monocytic MDSCs fail to maximally accumulate in the glioma 
microenvironment in the absence of CCL2
To delineate the requirement for CCL2 for the trafficking of Tregs and MDSCs to the tumor 
microenvironment, we implanted GL261 cells into Ccl2−/− mice and analyzed the brain 
tumor infiltrate at 1 week post-implantation. In the absence of CCL2, fewer Tregs (wild-type 
B6 ~1.52 × 104, Ccl2−/− ~6.46 × 103, P = 0.0260, mean absolute numbers of 
CD3+CD4+Foxp3+ Tregs) and monocytic Ly-6C+ MDSCs (wild-type B6 ~7.21 × 104, 
Ccl2−/− ~1.26 × 104, P = 0.0072, mean absolute numbers of 
CD45highCD11c−CD11b+Ly-6C+ monocytic MDSCs) infiltrated the brain tumor in terms of 
absolute numbers (Figure 5A–5B). Interestingly, the number of infiltrating granulocytic 
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Ly-6G+ MDSCs remained unchanged despite the lack of CCL2 (Figure 5C). These results 
indicate that both Tregs and monocytic MDSCs (but not granulocytic MDSCs) require 
CCL2 for maximal recruitment to gliomas. In addition, these results further support our 
finding that the glioma microenvironment is the primary source of CCL2, since the GL261 
cells implanted into Ccl2−/− were CCL2-competent.
Tregs are disproportionately dependent on CCR4 for trafficking to glioma in comparison to 
effector T cells
Given CCR4 expression on Tregs and CD4+Foxp3− T cells, we next determined the 
requirement for CCR4 for brain tumor trafficking. We generated mixed-bone marrow 
chimeras using bone marrow from wild-type CD45.1+ and CD45.2+ Ccr4−/− mice, injected 
the chimeras with GL261 cells, and analyzed the tissues after 1 week (Figure 5D). A slight 
deficiency was observed across all T cell populations within CD45.2+ cells in the brain: Treg 
(CD45.1+ WT 70.32 vs. CD45.2+ Ccr4−/− 20.23, P < 0.0001, mean frequency), 
CD4+Foxp3− (CD45.1+ WT 57.34 vs. CD45.2+ Ccr4−/− 31.17, P < 0.001), and CD8+ 
(CD45.1+ WT 56.45 vs. CD45.2+ Ccr4−/− 33.20, P < 0.0001) (Figure 5E). However, Treg 
accumulation in the brain was disproportionately affected by the absence of CCR4, as both 
CD4+Foxp3− T cell/Treg ratios (CD45.1+ WT 0.79 vs. CD45.2+ Ccr4−/− 1.53, P = 0.0025, 
absolute number ratio) and CD8+ T cell/Treg ratios (CD45.1+ WT 0.61 vs. CD45.2+ 
Ccr4−/− 1.29, P = 0.0018, absolute number ratio) were higher in CD45.1+ cells compared to 
CCR4-deficient CD45.2+ cells (Figure 5F). CCR4 deficiency had the greatest impact on 
Treg accumulation in the brain, as the ratio of CD45.1+/CD45.2+ cells was significantly 
higher among brain tumor-infiltrating Tregs compared to mesenteric lymph nodes (mLNs), 
cLNs, and spleen (Figure 5G). In contrast, the CD45.1+/CD45.2+ ratio among CD8+ T cells 
was similar across tissues (Figure 5G). Monocytic Ly-6C+ MDSCs were not affected by 
CCR4 deficiency and granulocytic Ly-6G+ MDSC numbers were only marginally affected 
(Supplementary Figure S4). Taken together, these results suggest that CCR4 plays a role in 
the trafficking of T cells to the brain, but is selectively relevant to the recruitment of brain 
tumor-infiltrating Tregs.
The CCL2-CCR4 chemokine-chemokine receptor interaction is a potential therapeutic 
target in glioma
We next hypothesized that targeting the CCL2-CCR4 interaction would decrease Treg 
recruitment in brain tumors. We first assessed the specificity and activity of the small 
molecule CCR4 antagonist C 021 in vitro. C 021 treatment abrogated Treg chemotaxis to the 
CCR4 cognate chemokines CCL17 and CCL22 but did not affect Treg migration to RPMI 
containing 10% FBS and CCL21 (Supplementary Figure S5A–B). To determine the in vivo 
activity of C 021, we treated GL261-implanted mice with 15 mg/kg C 021 administered by 
subcutaneous injection every other day for five total doses. C 021-treated mice gained a 30% 
improvement in median survival over vehicle control-treated mice with a commensurate 
decrease of CCR4+ Tregs and Ly-6G+ MDSCs while infiltrating CD4+ and CD8+ T cells 
were increased (Supplementary Figure S6A–6G). In addition, both CD4:Treg and CD8:Treg 
ratios were improved in C 021-treated mice (Supplementary Figure S6H–I). Furthermore, 
dose escalation experiments revealed that 15 mg/kg C 021 was sufficient to improve overall 
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survival (Figure 5H). Thus, the CCR4 chemokine inhibitor selectively inhibits Treg 
accumulation with the benefit of improved median survival.
Monocytic Ly-6C+ MDSCs that lack CCR2 do not accumulate in glioma
Since CCR2 expression was largely localized to MDSCs, we performed a similar mixed-
bone marrow chimera competition assay using wild-type CD45.1+ bone marrow and 
CD45.2+ CCR2-deficient bone marrow (Ccr2RFP/RFP) (Figure 6A) (26). Within the CD45.2+ 
CCR2-deficient department, we observed an almost complete lack of Ly-6C+ monocytic 
MDSCs (Figure 6B). Ly-6G+ granulocytic MDSCs were unaffected by the absence of CCR2 
in terms of trafficking to the brain tumor. Therefore, monocytic Ly-6C+ MDSCs require 
CCR2 in order for their ultimate accumulation in the GL261 tumors.
DISCUSSION
The immunosuppressive tumor microenvironment remains a major obstacle that impedes 
productive anti-tumor immune responses. Here, we have dissected a novel mechanism for 
Treg and MDSC recruitment that begins with tumor-derived CCL20 and osteoprotegerin 
inducing CCL2 production from glioma-associated macrophages and microglia. This 
mechanistic axis illustrates the potential of macrophages as an additional source of CCL2 in 
GBM patients. In the tumor microenvironment, astrocytoma cells are not only capable of 
producing CCL2 themselves but are also able to induce glioma-associated myeloid cells to 
secrete CCL2. Importantly, tumor-derived CCL2 and macrophage-derived CCL2 are not 
necessarily mutually exclusive possibilities. CCL2 then recruits Tregs and MDSCs through 
CCR4 and CCR2, respectively, as major contributors to the potently immunosuppressive 
glioma microenvironment.
The pro-tumorigenic or anti-tumorigenic effects of CCL2 are heavily context-dependent. 
CCL2-mediated recruitment of MDSCs, monocytes, and macrophages supports colorectal 
carcinogenesis, endometrial cancer growth, and breast cancer metastasis (27–29). However, 
anti-CD40 agonist treatment induces CCL2-recruited monocytes degrade fibrosis in an 
IFNγ-dependent manner, improving gemcitabine efficacy in pancreatic carcinoma (30). 
CCL2 can also recruit functional antigen-presenting cells in the context of chemotherapy, in 
which immunogenic cell death is likely to be of major importance (31). Thus, tumors with 
high amounts of CCL2 may be poised for the induction of a productive immune response if 
sufficient IFNγ or strongly immunogenic cell death can be induced. In the absence of such 
initiation, the monocytes and macrophages recruited by CCL2 instead contribute to the 
immunosuppressive microenvironment together with Tregs trafficking in response to CCL2.
In our mixed-bone marrow chimera studies, we observed some reduction across Treg, 
CD4+Foxp3−, and CD8+ T cell populations within the CD45.2+ Ccr4−/− cells compared to 
CD45.1+ wild-type cells. Interestingly, this may reflect a minor role for CCR4 in an earlier 
developmental stage. Aire-dependent expression of CCR4 has been shown to occur during 
the development of multiple αβ T cell lineages in the thymus, although CCR4 was not 
unanimously found to be required for T cell development in these studies (32,33). Thus, 
CCR4 may play a role in the T cell lineage at the common lymphocyte progenitor stage, 
during thymic emigration, or even at the level of systemic circulation.
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Our observation that MDSC accumulation did not occur in the CCR2-deficient cell 
compartment parallels other findings that CCR2 deficiency impairs circulating monocyte-
dendritic cell progenitors and monocyte progenitors (34). While our analysis does not 
absolutely decouple the requirement of CCR2 for monocyte trafficking/MDSC trafficking to 
glioma from that of an earlier monocyte progenitor role, it does confirm a role for CCR2 in 
the accumulation of glioma-infiltrating monocytic Ly-6C+ MDSCs. Furthermore, differential 
MDSC subset sensitivity to both CCL2 and CCR2-deficiency is meaningful given that the 
monocytic MDSC lineage was recently identified as more immunosuppressive in EG7, 
Lewis lung carcinoma, and B16 tumors (35). Therefore, further characterization of MDSCs 
in GBM patients remains an area of considerable interest.
The therapeutic benefit of CCR4 inhibition highlights the potential for other modalities of 
targeting CCR4, such as with therapeutic antibodies. Mogamulizumab, a defucosylated 
humanized CCR4 antibody with demonstrated efficacy in T cell lymphomas, has been 
adapted for targeting Tregs in solid tumors in a Phase Ia clinical trial (36–38). CCR4/2 
targeting is likely to be most effective in combination with immunotherapeutic approaches 
that activate the effector response, such as checkpoint blockade or vaccination in order to 
overcome immunosuppression at the tumor site while preventing the additional recruitment 
of immunosuppressive cells.
CCL2 is likely part of a larger gene expression signature that determines the presence of 
tumor-infiltrating lymphocyte (TIL)/MDSC/Treg infiltration in GBM (39–43). As the 
emphasis on translating immunotherapy for GBM patients continues to be a priority, 
identifying factors underlying Treg, MDSC, and TIL recruitment in brain tumors is vital for 
the strategic disarming of critical immune evasion pathways. Our findings highlight the 
impact of microenvironment-derived CCL2 in the accumulation of immunosuppressive cells 
and provide additional critical insight into the barriers that must be overcome for the 
successful translation of immunotherapies to treat GBM.
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Figure 1. CCL2 is a clinically relevant chemokine in GBM on a transcript and protein level
(A) Kaplan-Meier survival curves of glioma patients (Grade I–IV) were generated from 
TCGA Illumina HiSeq data where patients were segregated into CCL2-low and CCL2-high 
expressing groups on the basis of <mean - 0.5SD (for CCL2-down) and >mean + 0.5SD 
(CCL2-up) (CCL2-down, n = 161; CCL2-up, n = 159). (B) Analysis restricted to GBM 
(Grade IV) patients for both Illumina HiSeq (CCL2-down, n = 42; CCL2-up, n = 41) (top) 
and Affymetrix U133A (CCL2-down, n = 135; CCL2-up, n = 134) (bottom) arrays. (C) 
Representative images from GBM tissue microarray. Pathology scoring from left to right: 0, 
2, 2 on a scale of 0–3. Scale bar = 200 μm. (D–G) Pearson correlation between gene 
expression from GBM patient data of CCL2 expression and CD4, CD33, CD14, and CD3. 
GBM, glioblastoma mutiforme. TCGA, the Cancer Genome Atlas. Kaplan-Meier curves 
were compared using the Log-rank test. RNA Expr., relative mRNA expression.
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Figure 2. Myeloid cells are major sources of CCL2 in GBM patients and GL261 tumors
(A) Double-immunofluorescence labeling of CD163 and CCL2 in GBM patient tumor 
samples. Scale bar = 50 μm. Arrows, CCL2-positive, CD163-positive cells. (B) Sections of 1 
week post-GL261 implanted or control brains stained for CCL2, CD11b, and Iba1. Dashed 
line indicates tumor border. Scale bar = 10 μm. (C) Intracellular cytokine staining of CCL2 
in CD45highCD11b+Ly-6G+ macrophages and CD45intCD11b+ microglia. (D) 
CD45intCD11b+ microglia were sorted from tumor-bearing mice (n = 5) and gene 
expression was analyzed by qRT-PCR compared to PBS-injected mice. (E) Expression of 
M1- and M2-associated genes in glioma-associated microglia and macrophages compared to 
peripheral macrophages and CD45highCD11b−CD11c+ dendritic cells (DCs) isolated from 
spleens within the same mice. Images and plots in (B–C) are representative of 3 independent 
replicates. Data are representative of at least 2 independent experiments. Data in A are 
represented as mean ± SEM; **** P < 0.0001 by Student’s t test.
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Figure 3. Soluble tumor-derived factors induce CCL2 secretion by macrophages and microglia
(A) Bone marrow-derived macrophages (BMDMs) were treated for 24 hours with cytokines 
or media containing 50% GL261 cell supernatant. Supernatant was collected after another 
48 hours for CCL2 analysis by ELISA. S/N control denotes the CCL2 content in GL261 
supernatant. (n = 3–6) (B) Microglia from neonatal mixed-cortical cell cultures (MCCC) 
were treated with the indicated cytokines or with media containing GL261 supernatant. (n = 
3). (C–D) Mouse cytokine array from MCCC or GL261 supernatant. (E–F) CCL2 secretion 
from BMDMs treated with candidate cytokines/chemokines identified from the antibody 
arrays (n = 3–6). (G) CCL2 secretion from microglia treated with candidate cytokines/
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chemokines (n = 3). Data in A, B, E–G are representative of 3–4 independent experiments. 
Data are represented as mean ± SEM; *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 
0.0001 by ordinary one-way ANOVA with Tukey’s multiple comparisons test.
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Figure 4. GL261 tumors are infiltrated by CCR4-expressing Tregs and CCR2-expressing MDSCs
(A–B) Flow cytometric quantification of CCR4 and CCR2 expression among CD4+Foxp3− 
T cells, CD4+Foxp3+ Tregs, and CD8+ T cells (n = 5). (C–D) Quantification of CCR4 and 
CCR2 expression on T cell subsets in brain compared to cervical lymph nodes and spleen 
(E–F) Absolute numbers of CD11b+Ly-6G+ and CD11b+Ly-6C+ cells in the brains of tumor 
bearing or PBS-injected mice (n = 5). (G) CCR4 and CCR2 expression in MDSC subsets 
and microglia. (H) Quantification of frequencies in G (n = 5). Data are representative of at 
least 4 independent experiments. Data are represented as mean ± SEM; *P < 0.05, **P < 
0.01, ***P < 0.001, and ****P < 0.0001 by ordinary one-way ANOVA with Tukey’s 
multiple comparisons test in B, D, and H or Student’s t test in E–F. cLN, cervical lymph 
nodes. Sp, spleen.
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Figure 5. Mechanistic requirements of CCL2 and CCR4 for trafficking to glioma
(A–B) Treg infiltration at 1 week post-i.c. GL261 in wild-type C57BL/6 (B6) or Ccl2−/− 
mice. (n = 4). (C) MDSC infiltration in brain tumors of wild-type B6 mice or Ccl2−/− mice. 
(D) Schematic of mixed-bone marrow chimera (BMC) experiments using wild-type 
CD45.1+ and CD45.2+ Ccr4−/− marrow. (E) Flow cytometric analysis of BMC experiments 
of WT vs. Ccr4−/− cells within the T cell compartment. (n = 8) (F) CD4/Treg ratio and CD8/
Treg ratio within CCR4-deficient cells or wild-type cells in brain tumor-bearing chimeric 
mice (n = 8). (G) CD45.1+/CD45.2+ cell ratios in Treg or CD8+ T cell compartments across 
tissues in brain tumor-bearing chimeric mice (n = 8). (H) End-point analysis of mice 
implanted with GL261 cells and treated on alternating days with indicated doses of CCR4 
antagonist (C 021) for a total of 5 doses. Data are representative of 2–3 independent 
experiments. Data are represented as mean ± SEM; *P < 0.05, **P < 0.01, ***P < 0.001, 
and ****P < 0.0001 by Student’s t test in B,C, E, F or ordinary one-way ANOVA with 
Tukey’s multiple comparisons test in G. Kaplan-Meier survival curves were compared with 
the Log-rank test with the Bonferroni method for multiple comparisons.
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Figure 6. Ly-6C+ monocytic MDSCs require CCR2 for accumulation in glioma
(A) Schematic of mixed-bone marrow chimera experiments using wild-type CD45.1+ and 
CD45.2+ Ccr2RFP/RFP (CCR2-deficient) marrow. (B) Wild-type CD45.1+ or CCR2-deficient 
CD45.2+ glioma-infiltrating MDSC subsets in brain tumor-bearing chimeric mice (n = 7). 
Data are representative of at least 2 independent experiments. Data are represented as mean 
± SEM; *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 by Student’s t test.
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Figure 7. A model describing the CCL2-CCR4/2 axis in GBM
Glioma-derived CCL20 and OPG induces the production of CCL2 from glioma-associated 
macrophages and microglia. CCL2 recruits CCR4-expressing Tregs and CCR2-expressing 
monocytes to GBM. These monocytes then differentiate into CCR2+ MDSCs.
Chang et al. Page 21
Cancer Res. Author manuscript; available in PMC 2017 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
